To mark International Day of Women and Girls in Science 2026, we interviewed several of our DPhil in Cancer Science students and alumnae to discuss what motivated them to pursue careers in cancer research. Hear from first-year Fundamental Scientist Safiyah Mohamed, who is currently working in the Department of Clinical Neurosciences on research aiming to understand the biology of adult brain tumours.
To mark International Day of Women and Girls in Science 2026, we interviewed several of our DPhil in Cancer Science students and alumnae to discuss what motivated them to pursue careers in cancer research. Hear from first-year Clinical Research Training Fellow Jess Caterson, who works at the Big Data Institute in the Nuffield Department of Population Health on research aiming to help modernise and digitalise surgical care through the use of wearable technology.
The World Cancer Day theme 2025-2027 \u201cUnited by Unique\u201d places people at the centre of care and their stories at the heart of the conversation. At Oxford Cancer, we are committed to supporting Patient and Public Involvement (PPI) in research; we aim to build an inclusive community of PPI representatives who are involved in the design and delivery of cutting-edge cancer projects.
A new state-of-the-art high-intensity focused ultrasound (HIFU) machine has been installed at the Churchill Hospital, giving Oxford University Hospitals (OUH) cancer patients access to the latest in this innovative technology.
Catriona Gilmour Hamilton, Oxford Cancer's Patient and Public Involvement (PPI) Manager, discusses our brand new PPI-Led Pump Priming Scheme, which will launch in Spring 2026.
A new clinical study has launched to investigate whether insulin levels influence how women with the most common type of breast cancer respond to treatment.
Researchers from the Jiang Group in the Department of Oncology have published Phase Ia clinical trial results for OVM-200, a novel cancer vaccine targeting survivin. The first-in-human trial, published in eClinicalMedicine, reports promising early safety and immunogenicity findings in patients with advanced solid tumours.
A new study from the Dushek and van der Merwe labs in the Sir William Dunn School of Pathology demonstrates a novel strategy to reduce dangerous off-target effects in engineered T cell therapies.
Congratulations to the following DPhil in Cancer Science students \u2014 Michael Bryan, Eva Hanlon, Raul Cioca, Aglaia Skolariki, Nicole Cianci, Roy Rosman Nathanson, Alexandra Petukhova-Greenstein, Anna Prazmo, and Dylan Muldoon \u2014 who have been awarded research funding through the 2025 DPhil in Cancer Science Onco-Innovation Project Sandpit.
Eight mid-career researchers identified as having the potential to become future leaders in translational research have been appointed to the next cohort of NIHR Oxford Senior Research Fellows. Those named include Rubeta Matin, Oxford Research Lead for Dermatology Skin Cancer Clinical Trials, and Dr Sarah Gooding, Cancer Research UK Clinician Scientist based at the Weatherall Institute of Molecular Medicine.
A recent article on cancer inequalities - written by Cancer Research UK experts, including Oxford's MRC WIMM Director, Professor KJ Patel - discusses why inclusive research is essential to beat cancer for everyone.
2nd place was awarded to Nathalie L\u00f6vgren, DPhil Student, and Dr Iain Tullis, Senior Postdoctoral Researcher, in the Physics and Biology of FLASH Radiation Research Group at the University of Oxford. Nathalie and Iain's snowflake-inspired image was based on their work investigating a potential new radiation treatment for cancer.
The Translational Histopathology Laboratory (THL), part of the Oxford Experimental Cancer Medicine Centre (ECMC), has achieved Good Clinical Laboratory Practice (GCLP) accreditation, marking an important milestone in the delivery of high-quality, standardised tissue analysis for the cancer research community in Oxford.
Kendra Perez-Smith, Translational Support Unit (TSU) Manager in the Department of Oncology, has received an Outstanding Contribution to Sustainability Award in recognition of her innovation and leadership in establishing Lab QuTe: a department-wide network designed to reduce the environmental impact of clinical trials.
Researchers at the University of Oxford have developed TrustedMDT, a multi-agent artificial intelligence (AI) system designed to support medical specialists during cancer treatment planning meetings.
The Ministry of Health of Brazil and Oxford\u2019s Centre for Immuno-Oncology, part of the Nuffield Department of Medicine, have signed a Letter of Intent establishing a broad collaboration to advance cancer research, innovation and clinical translation. The agreement builds on the UK-Brazil Government Health Partnership signed earlier this year, and reflects a shared commitment to accelerating research that will lead to improvements in cancer care across Brazil.
A new editorial published in the British Journal of General Practice examines how recent research presents an opportunity to refresh how risk thresholds are applied in national primary care cancer referral guidelines. This article was written by Brian Nicholson, Associate Professor in the Nuffield Department of Primary Care Health Sciences, in collaboration with academic thought-leaders from across the UK and CRUK.
Keaton Jones, Consultant Hepatobiliary and Pancreatic Surgeon at Oxford University Hospitals NHS Foundation Trust and Senior Clinical Researcher in the Department of Oncology at the University of Oxford, has received a Wellcome Trust Early Career Award to investigate the role of macrophage metabolism in determining therapeutic responses in pancreatic cancer.
Are you interested in public engagement with cancer research? Julliet Lwiindi, Oxford Cancer's Public Engagement and Involvement Officer, shares a little about the ways in which you can engage with our Oxford Cancer Patient and Public Involvement (PPI) group.
The MAPK pathway is a cell signalling pathway that helps cells respond to external signals and convert them into specific actions. Colorectal cancer (CRC) often has a stubborn resistance to therapies, particularly when it is caused by mutations in the MAPK pathway.
![\"\"](\"https://www.cancer.ox.ac.uk/news/international-day-of-women-and-girls-in-science-safiyah/responsive_image?ratio=r16x9&scale=w760\")
\n \n \n\n\n